AngioDynamics (NASDAQ:ANGO) Releases FY20 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.25-0.30 for the period, compared to the Thomson Reuters consensus estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.90 million.AngioDynamics also updated its FY 2020 guidance to $0.25-0.30 EPS.

Shares of NASDAQ ANGO opened at $21.68 on Friday. The company’s 50 day moving average is $19.62. AngioDynamics has a 52 week low of $18.11 and a 52 week high of $25.48. The company has a quick ratio of 1.70, a current ratio of 4.30 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $814.66 million, a PE ratio of 26.69 and a beta of 0.69.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing the consensus estimate of $0.26 by ($0.01). AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The company had revenue of $96.30 million for the quarter, compared to analyst estimates of $92.34 million. During the same period last year, the company posted $0.20 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. As a group, sell-side analysts forecast that AngioDynamics will post 0.27 earnings per share for the current fiscal year.

ANGO has been the subject of several recent research reports. ValuEngine cut Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. TheStreet cut Upland Software from a b- rating to a c+ rating in a research report on Wednesday. BidaskClub raised Westport Fuel Systems from a hold rating to a buy rating in a research report on Friday. Finally, Zacks Investment Research raised Investar from a hold rating to a buy rating and set a $27.00 price target for the company in a research report on Tuesday, June 4th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $21.50.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Further Reading: Preferred Stock

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.